EP3470432

REGENERON PHARMACEUTICALS, INC.
Application Number
EP18194745A
Filing Date
Aug 20, 2013
Status
Revoked
May 19, 2023
Grant Date
Oct 6, 2021
External Links
Slate, Register

Biblio Summary

The patent EP3470432B1 was granted on Oct 6, 2021 by Regeneron Pharmaceuticals, Inc. The patent is currently Revoked.

The table below shows 4 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

D YOUNG & CO LLPJul 6, 2022ADMISSIBLE
NEUEFEIND, REGINAJul 6, 2022ADMISSIBLE
DR. H. ULRICH DORRIESJul 5, 2022ADMISSIBLE
SECERNA LLPJul 5, 2022ADMISSIBLE

The table below shows the patents of Regeneron Pharmaceuticals, Inc. that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3110848Methods For Treating Skin Infection By Administering An Il-4R AntagonistFeb 14, 20245
EP3515465Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorFeb 7, 20247
EP3973987Methods For Treating Or Preventing Asthma By Administering An Il-4R AntagonistJan 10, 20246

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.